Trial Profile
Study of Pulmonary Rehabilitation In Nintedanib Treated Patients With IPF: Improvements in Activity, Exercise Endurance Time, and QoL
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 11 Jun 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 10 Jul 2020 Status changed from recruiting to discontinued, due to the current COVID-19 pandemic, the recruitment of new subjects is temporarily discontinued. Ongoing, randomised patients are managed per Trial Protocol.
- 04 Jun 2020 Planned End Date changed from 19 May 2022 to 15 Jun 2020.
- 04 Jun 2020 Planned primary completion date changed from 19 May 2022 to 15 Jun 2020.